Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Biologics CDMO Industry?

The advancement in the biologics CDMO market has been quite swift in the past few years. The market size is projected to escalate from $21.3 billion in 2024 to $24.15 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.4%. The growth witnessed in the historic period is influenced by factors such as the emergence of biologics development, cost efficiency and adaptability, emphasis on core competencies, assurance of regulatory compliance and quality, and the global expansion of pharmaceutical supply chains.

The market size of the biologics CDMO is anticipated to witness expedited growth in the upcoming years, expanding to “$41.53 billion in 2029” with a compound annual growth rate (CAGR) of “14.5%”. Multiple factors will contribute to this growth pattern in the predicted timeframe, including the growing need for biologic therapies, the rise of biosimilars and biobetters, investments flowing into biomanufacturing infrastructure, the move towards outsourcing intricate processes, emphasis on maintaining resilience in the supply chain and mitigating risks, regulatory harmonization, and fast-tracked approvals. Notable trends over the forecast period comprise expansion of capabilities to deliver comprehensive solutions, the incorporation of single-use technologies, the inclusion of continuous manufacturing processes, and the emergence of specialized CDMOs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp

What Forces Are Driving The Growth Of The Biologics CDMO Industry?

The biologic CDMO market is anticipated to grow due to the increasing demand for cell and genetic therapy. These innovative medical strategies use living cells or genetic material to address disease causes at the cellular or genetic level. They provide potential remedies for conditions otherwise difficult to treat or cure with conventional medications. The rising demand for these therapies is attributed to their groundbreaking approach in disease treatment, tackling underlying genetic or cellular causes. Biologic CDMOs offer expertise in dealing with living cells, viral vectors, and genetic material. They promote safe and effective production of cell and gene therapies and assist biopharmaceutical companies in meeting regulatory standards and technical obstacles, hence promoting the transition from research to clinical application. For example, The American Society of Gene & Cell Therapy (ASGCT), a top professional membership organization based in the U.S., reported in January 2023 that the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, reaching a total of 3,726 therapies under development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the rising demand for cell and genetic therapy is fueling the growth of the biologic CDMO market.

The biologics cdmo market covered in this report is segmented –

1) By Cell Type: Mammalian, Non-Mammalian

2) By Product Type: Biologics, Biosimilars

Subsegments:

1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells

2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells

How Are Key Trends Driving Expansion In The Biologics CDMO Industry?

Leading entities in the biologics CDMO industry are engineering technologically superior solutions, including novel cell lines, to bolster the efficacy and capabilities of biopharmaceutical development and manufacturing. This innovation leads to the creation of more potent therapeutic antibodies, thereby resolving issues faced in R&D for immunotherapy. For example, Lonza Group, a Swiss manufacturing corporation renowned in the pharma and biotech fields, unveiled their GS Effex cell lines in November 2023. These are intended for generating antibodies that are entirely devoid of fucose, a type of sugar molecule, and exhibit boosted potency without sacrificing other performance factors. This initiative aids in tackling problems associated with augmenting the potency of antibody therapeutics in immunotherapy R&D. The GS Effex cell lines are stable and scalable, offering a viable approach for therapeutic advancement that serves processes from discovery-stage investigation to commercial-scale manufacturing.

Who Are The Primary Players Operating Across The Global Biologics CDMO Market?

Major companies operating in the biologics CDMO market are AbbVie Inc., Thermo Fisher Scientific Inc., Novartis AG, Evonik Industries AG, Sandoz International GmbH, ICON PLC, Grifols SA, Lonza Group Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., JSR Corp., Parexel International Corporation, WuXi Biologics (Cayman) Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., Rentschler Biopharma SE, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Binex Co. Ltd., Bora Pharmaceuticals Co. Ltd, 3P Biopharmaceuticals s.l.u, JRS Pharma LP, J Rettenmaier and SOHNE GmbH and Co KG, Kemwell Biopharma Pvt. Ltd., Cytovance Biologics, AGC Biologics, Shenzhen Hepalink Pharmaceutical Co. Ltd.

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Which Region Offers The Most Growth Potential For The Biologics CDMO Market Through 2029?

North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model